All In Biotech

Drug Trial Radar · NCT06658899

A Phase 2 Study of CRD-4730 in CPVT

A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.

Conditions

  • Catecholaminergic Polymorphic Ventricular Tachycardia

Interventions

  • CRD-4730Drug

    Oral CRD-4730 in tablet form

  • PlaceboDrug

    Placebo to match CRD-4730 in tablet form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome MeasuresTime frame: Baseline to Day 101

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Cardurion Investigative Site

    San Francisco, California · Recruiting

  • Cardurion Investigative Site

    Morrisville, North Carolina · Recruiting

  • Cardurion Investigative Site

    Houston, Texas · Recruiting

  • Cardurion Investigative Site

    Salt Lake City, Utah · Recruiting

  • Cardurion Investigative Site

    Madison, Wisconsin · Recruiting

  • Cardurion Investigative Site

    Vancouver, British Columbia, Canada · Recruiting

  • Cardurion Investigative Site

    Bron, France · Recruiting

  • Cardurion Investigative Site

    Paris, France · Recruiting

  • Cardurion Investigative Site

    Saint-Herblain, France · Recruiting

  • Cardurion Investigative Site

    Pavia, Pavia, Italy · Recruiting

  • Cardurion Investigative Site

    Amsterdam, North Holland, Netherlands · Recruiting

  • Cardurion Investigative Site

    Esplugues de Llobregat, Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.